Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Aeglea BioTherapeutics stock
Own Aeglea BioTherapeutics stock in just a few minutes.
Aeglea BioTherapeutics, Inc is a biotechnology business based in the US. Aeglea BioTherapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea BioTherapeutics employs 90 staff and has a market cap (total outstanding shares value) of USD$376 million.
How to buy shares in Aeglea BioTherapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Aeglea BioTherapeutics. Find the stock by name or ticker symbol: AGLE. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aeglea BioTherapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aeglea BioTherapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Aeglea BioTherapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Aeglea BioTherapeutics share price
Use our graph to track the performance of AGLE stocks over time.Aeglea BioTherapeutics shares at a glance
Information last updated 2021-04-08.
| 52-week range | USD$4.91 - USD$11.38 |
|---|---|
| 50-day moving average | USD$7.7094 |
| 200-day moving average | USD$7.9371 |
| Wall St. target price | USD$15.86 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.299 |
Buy Aeglea BioTherapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aeglea BioTherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aeglea BioTherapeutics financials
| Gross profit TTM | USD$-59,638,000 |
|---|---|
| Return on assets TTM | -41.61% |
| Return on equity TTM | -80.93% |
| Profit margin | 0% |
| Book value | $2.916 |
| Market capitalisation | USD$376 million |
TTM: trailing 12 months
Shorting Aeglea BioTherapeutics shares
There are currently 2.0 million Aeglea BioTherapeutics shares held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 11.4% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics shares can be evaluated.
Aeglea BioTherapeutics's "short interest ratio" (SIR)
Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics shares currently shorted divided by the average quantity of Aeglea BioTherapeutics shares traded daily (recently around 195250.96711799). Aeglea BioTherapeutics's SIR currently stands at 10.34. In other words for every 100,000 Aeglea BioTherapeutics shares traded daily on the market, roughly 10340 shares are currently held short.
However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics shares, or, against the total number of tradable Aeglea BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aeglea BioTherapeutics shares in existence, roughly 40 shares are currently held short) or 0.0448% of the tradable shares (for every 100,000 tradable Aeglea BioTherapeutics shares, roughly 45 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aeglea BioTherapeutics.
Find out more about how you can short Aeglea BioTherapeutics stock.
Aeglea BioTherapeutics share dividends
We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months.
Aeglea BioTherapeutics share price volatility
Over the last 12 months, Aeglea BioTherapeutics's shares have ranged in value from as little as $4.91 up to $11.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.6837. This would suggest that Aeglea BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeglea BioTherapeutics overview
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Frequently asked questions
More guides on Finder
-
How to buy New Source Energy stock
Steps to owning and managing NSE, with 24-hour and historical pricing before you buy.
-
How to buy New Providence Acquisition stock
Steps to owning and managing NPA, with 24-hour and historical pricing before you buy.
-
How to buy New Frontier Health Corporation stock
Steps to owning and managing NFH, with 24-hour and historical pricing before you buy.
-
How to buy NextEra Energy Partners stock
Steps to owning and managing NEP, with 24-hour and historical pricing before you buy.
-
How to buy New England Realty Associates Limited Partnership stock
Steps to owning and managing NEN, with 24-hour and historical pricing before you buy.
-
How to buy NETSTREIT stock
Steps to owning and managing NTST, with 24-hour and historical pricing before you buy.
-
How to buy Nortech Systems Incorporated stock
Steps to owning and managing NSYS, with 24-hour and historical pricing before you buy.
-
How to buy North American Construction Group stock
Steps to owning and managing NOA, with 24-hour and historical pricing before you buy.
-
How to buy Navios Maritime Partners L-P stock
Steps to owning and managing NMM, with 24-hour and historical pricing before you buy.
-
How to buy Navios Maritime Containers L-P stock
Steps to owning and managing NMCI, with 24-hour and historical pricing before you buy.
Ask an Expert